Table 2.
Crude recurrence rate % [No.] | Hazard ratio [95% CI] | |
---|---|---|
Stage I | P = 0.002 | P < 0.001 |
CLST A [78] | 3.8 [3] | 1.00 [ref.] |
B [23] | 17.4 [4] | 5.59 [1.25- 25.06] |
C [66] | 16.7 [11] | 4.96 [1.38- 17.78] |
D [20] | 35.0 [7] | 11.47 [2.96- 44.39] |
Stage IA | P = 0.007 | P < 0.001 |
CLST A [65] | 3.1 [2] | 1.00 [ref.] |
B [12] | 0.0 [0] | N.A. |
C [45] | 4.4 [2] | 1.53 [0.22- 10.89] |
D [8] | 37.5 [3] | 17.18 [2.82-104.69] |
Stage IB | P = 0.191 | P = 0.153 |
CLST A [13] | 7.7 [1] | 1.00 [ref.] |
B [11] | 36.4 [4] | 7.45 [0.82- 67.44] |
C [21] | 42.9 [9] | 7.82 [0.99- 61.94] |
D [12] | 33.3 [4] | 5.77 [0.64- 51.67] |
ARC-CLSTs, clusters based on architectural elements; No., number of cases; CLST, cluster; P, P value for crude reccyrrence rate and harad ratio are calculated by Fisher's exact test and and Log-rank test, respectively; CI, confidence interval; ref., reference; N.A., not available Squamous cell carcinomas were excluded from analysis.